ITERUM THERAPEUTICS PLC(NASDAQ:ITRM) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ITRM. ITRM was compared to 198 industry peers in the Pharmaceuticals industry. ITRM may be in some trouble as it scores bad on both profitability and health. ITRM is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ITRM had negative earnings in the past year.

ITRM had a negative operating cash flow in the past year.

ITRM had negative earnings in each of the past 5 years.

ITRM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ITRM's Return On Assets of -55.55% is on the low side compared to the rest of the industry. ITRM is outperformed by 62.63% of its industry peers.

		Industry Rank	Sector Rank
ROA	-55.55%
ROE	N/A
ROIC	N/A

ROA(3y)-104.22%

ROA(5y)-174.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ITRM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ITRM has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ITRM has more shares outstanding

Compared to 1 year ago, ITRM has a worse debt to assets ratio.

2.2 Solvency

ITRM has an Altman-Z score of -15.90. This is a bad value and indicates that ITRM is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -15.90, ITRM is not doing good in the industry: 79.29% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-15.9

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ITRM has a Current Ratio of 1.41. This is a normal value and indicates that ITRM is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.41, ITRM is doing worse than 73.74% of the companies in the same industry.

ITRM has a Quick Ratio of 1.41. This is a normal value and indicates that ITRM is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.41, ITRM is not doing good in the industry: 66.16% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.41
Quick Ratio	1.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.78% over the past year.

EPS 1Y (TTM)55.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%75.53%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

ITRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.81% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y49.4%

EPS Next 2Y26.36%

EPS Next 3Y27.14%

EPS Next 5Y23.81%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ITRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITRM. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ITRM's earnings are expected to grow with 27.14% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.36%

EPS Next 3Y27.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ITRM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ITERUM THERAPEUTICS PLC

NASDAQ:ITRM (4/24/2025, 8:18:35 PM)

After market: 1.33 +0.03 (+2.31%)

1.3

-0.09 (-6.47%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-07 2025-02-07/bmo

Earnings (Next)05-09 2025-05-09

Inst Owners4.35%

Inst Owner Change0%

Ins Owners1.19%

Ins Owner Change0%

Market Cap44.95M

Analysts82.5

Price Target7.65 (488.46%)

Short Float %4.49%

Short Ratio4.62

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-25.97%

Min EPS beat(2)-47.06%

Max EPS beat(2)-4.88%

EPS beat(4)2

Avg EPS beat(4)5.12%

Min EPS beat(4)-47.06%

Max EPS beat(4)37.8%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)21.05%

EPS NQ rev (3m)14.29%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)100.07%

Revenue NQ rev (3m)100.07%

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.29

EYN/A

EPS(NY)-0.65

Fwd EYN/A

FCF(TTM)-1.14

FCFYN/A

OCF(TTM)-1.14

OCFYN/A

SpS0

BVpS-0.12

TBVpS-0.69

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-55.55%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-104.22%

ROA(5y)-174.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0.74%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.41
Quick Ratio	1.41
Altman-Z	-15.9

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)2.31%

Cap/Depr(5y)5.3%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)55.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%75.53%

EPS Next Y49.4%

EPS Next 2Y26.36%

EPS Next 3Y27.14%

EPS Next 5Y23.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y60.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-112.32%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-112.94%

OCF growth 3YN/A

OCF growth 5YN/A

ITERUM THERAPEUTICS PLC (ITRM) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens